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ABSTRACT
Aims: To compare effects of long-term treatment with GLP-1RA exenatide twice-daily versus titrated 
insulin glargine (iGlar) on renal function and albuminuria in type 2 diabetes (T2DM) patients.
Methods: We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean±SD age 
60±8years, HbA1c 7.5±0.9%, eGFR 86±16mL/min/1.73m2, median[IQR] urinary albumin-to-creatinine-
ratio (UACR) 0.75 [0.44-1.29]mg/mmol) randomised to exenatide 10µg twice-daily or titrated iGlar on-
top-of metformin for 52-weeks. Renal efficacy endpoints were change in creatinine clearance (CrCl) 
and albuminuria (urinary albumin-excretion [UAE] and UACR) based on 24-hour urines, collected at 
baseline and Week-52. eGFR and exploratory endpoints were collected throughout the intervention-
period, and after a 4-week wash-out.
Results: HbA1c-reductions were similar with exenatide (mean±SEM -0.80±0.10%) and iGlar (-
0.79±0.14%; treatment-difference 0.02%; 95%CI -0.31 to 0.42%). Change from baseline to Week-52 
in CrCl, UAE or UACR did not statistically differ; only iGlar reduced albuminuria (P<0.05;within-group). 
eGFR decreased from baseline to Week-4 with exenatide (-3.9±2.1mL/min/1.73m2;P=0.069) and iGlar 
(-2.7±1.2mL/min/1.73m2;P=0.034), without treatment-differences in ensuing trajectory. Exenatide 
versus iGlar reduced bodyweight (-5.4kg; 2.9 to 7.9;P<0.001), but did not affect blood pressure, lipids 
or plasma uric acid.
Conclusions: Among T2DM patients without overt nephropathy, one-year treatment with exenatide 
twice-daily does not affect renal function-decline or onset/progression of albuminuria compared to 
titrated iGlar.
--------------------------------------
Key Words: GLP-1 receptor agonist, exenatide, insulin glargine, albuminuria, glomerular filtration rate,
diabetic kidney disease, renoprotection, type 2 diabetes mellitus
Trial registration: Clinicaltrials.gov ID: NCT00097500
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1│INTRODUCTION
Diabetic kidney disease (DKD) is the most common cause of chronic- and end-stage kidney disease, 
and increases patients’ risk of cardiovascular events and premature death.(1) DKD manifests clinically 
as albuminuria, impaired glomerular filtration rate (GFR), or both.(1) Intensified control of modifiable 
renal risk factors, and use of renin-angiotensin-system (RAS)-inhibitors, slows albuminuria progression 
and preserves renal function in at-risk patients with type 2 diabetes (T2DM). Nevertheless, residual 
renal risk remains high, and the absolute number of patients with DKD continues to rise in parallel with 
the T2DM-pandemic.(1) 
Glucagon-like peptide (GLP)-1 receptor agonists (RAs) are effective and well-tolerated glucose-
lowering drugs for the treatment of T2DM.(2) GLP-1RAs harbour a minimal hypoglycaemia-risk, often 
induce weight-loss, and are associated with modest reductions in blood pressure (BP) and circulating 
lipids.(1) Interestingly, GLP-1RAs were reported to prevent histological features of DKD in pre-clinical 
models, and improve renal biomarkers in placebo-controlled clinical trials “beyond glycaemic 
control”.(3) Three cardiovascular outcome-trials (CVOTs; ELIXA, LEADER and SUSTAIN-6) 
demonstrated that GLP-1RA-therapy, on top of standard-of-care, reduces onset and progression of 
albuminuria in high-risk T2DM patients during 2-4 years of follow-up.(4-7) In LEADER, liraglutide 
modestly slowed estimated GFR (eGFR)-decline compared to placebo at Month-36.(6) 
Mechanisms underlying the glucose-independent renoprotective properties of GLP-1RAs in T2DM 
remain uncertain. Proposed pathways comprise: 1) direct GLP-1R-mediated effects on the diabetic 
kidney (e.g. natriuresis and amelioration of glomerular hyperfiltration), and 2) indirect benefits via 
improvements in renal risk-profile (both classical factors [obesity, hypertension, dyslipidaemia] and 
emerging factors [e.g. plasma uric acid (PUA), oxidative-stress/inflammation]).(1,3) In order to 
carefully evaluate GLP-1RA-specific benefits on renal outcomes in RCTs, confounding effects of 
glucose-lowering per-se should be minimalised by warranting glycaemic-equipoise between treatment-
arms. Notably, in all CVOTs of GLP-1RAs published to date, treatment-differences in HbA1c were 
likely of clinical relevance in terms of reducing DKD-risk (time-averaged mean change from baseline 
~0.3-1.1%-points).(3) In ELIXA, the favourable effect of lixisenatide on progression of urinary albumin-
to-creatinine ratio (UACR) in all patients was attenuated (P=0.07) after correction for small HbA1c-
differences(4), suggesting an –at least partially– mediating effect of glucose-lowering.
Thus, long-term intervention trials in T2DM that evaluate renal outcomes should ensure glycaemic-
equipoise, preferably using head-to-head comparator designs, to justly assess benefits “beyond 
glycaemic control”, and enhance clinical relevance. In this post-hoc analysis of a 52-week RCT(8), we 
evaluated whether the short-acting GLP-1RA exenatide twice-daily slows renal function-decline and 
onset and progression of albuminuria compared to titrated insulin glargine (iGlar) in T2DM patients 
inadequately controlled on metformin.
2│MATERIALS AND METHODS
2.1│Design, participants and interventions
This is a post-hoc analysis of a randomised, open-label, active-comparator, parallel-group trial, 
performed at three study sites in Sweden, Finland and the Netherlands. The trial was originally 
designed to determine treatment-effects on clamp-measured beta-cell function after 52-weeks; 
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detailed design and methods were published previously.(8) In brief, 69 Caucasian T2DM patients 
(male and female, age 30-75 years, HbA1c 48-80 mmol/mol [6.5-9.5%], BMI 25-40 kg/m2) were 
randomised in a 1:1 ratio to receive exenatide twice-daily (N=36; Byetta®, AstraZeneca, London, UK) 
or titrated iGlar (N=33; Lantus®, Sanofi, Paris, France) for 52 weeks in addition to stable and ongoing 
metformin monotherapy (titration schemes in Appendix-S1). All patients in current analysis attended a 
follow-up visit 4 weeks after the last administration of the investigational-product, to explore reversible 
drug-effects. The study protocol was approved by the ethics committee at each participating centre, 
registered at ClinicalTrials.gov (NCT00097500), and was performed in accordance with the principles 
of the Declaration of Helsinki. Written informed consent was obtained from all patients.
2.2│Study endpoints
The primary renal efficacy endpoints for this analysis were change from baseline to Week-52 in 
creatinine clearance (CrCl) and urinary albumin excretion (UAE), both determined from 24-hour urine-
collections. Participants were given oral and written instructions on how to collect a 24-hour urine-
sample, and were instructed to postpone collection in case of fever, urinary-tract infection, or 
menstruation, and to refrain from strenuous exercise during the collection-period. Patients were 
advised to store the 24-hour urine-collections in dedicated containers, in the refrigerator for a 
maximum of 2 days prior to assay. We considered 24-hour urine-collections to be inadequate if 24-
hour urine creatinine-excretion was <10 or <8mg/kg of lean body mass (LBM; measured by DEXA-
scan, as described(9)) in men and women, respectively. CrCl is expressed as uncorrected-values, and 
BSA-standardised. Serum and urinary-creatinine and urinary-albumin were measured in a central 
laboratory by standard procedures. 
Secondary renal efficacy endpoints were change in UACR from baseline to Week-52, and changes 
in eGFR over time. Fasting serum creatinine was used to calculate eGFR using the MDRD Study-
equation. Difference between groups in the average rate of change in eGFR for three specified time-
periods were quantified; from baseline to Week-4 (period-1; to assess immediate treatment-effects, 
expectedly of renal haemodynamic-nature), from Week-4 to Week-52 (period-2; to assess long-term 
treatment-effects); from Week-52 to Week-56 (period-3; to assess reversible, conceivably 
haemodynamically-mediated, treatment-effects). Exploratory endpoints included trajectories and time-
averaged means (both absolute values and deltas) of HbA1c, fasting plasma glucose (FPG), fasting-
BP, fasting lipids and PUA.
2.3│Statistical analyses
All statistical analyses were performed using SPSS Statistics for Windows, V22.0 (IBM Corp., Armonk, 
NY), and done according to a statistical analysis plan agreed before data-inspection. Multivariable 
linear regression models were used to examine exenatide- compared to iGlar-induced effects after 52-
weeks; corresponding baseline-values were added as independent variables to correct for potential 
between-group differences pre-treatment. Within-group comparisons over specific time-periods were 
analysed using paired t-tests (for Gaussian-distributed data) or Wilcoxon signed rank tests (non-
Gaussian distributed data), as appropriate. Absolute and incremental/decremental time-averaged 
mean differences in risk factors were calculated, and analysed using independent samples t-tests. 
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Pearson’s and Spearman correlation analyses, as appropriate, were performed to explore individual 
associations between renal endpoint-data and time-averaged mean changes from baseline in 
prespecified risk factors. All P-values are from two-sided tests of the null hypothesis; an α-level of 0.05 
was regarded as statistical significant. Data are reported as mean ±SEM, median [interquartile range], 
baseline-corrected mean treatment-difference (95% confidence interval; CI), or frequency (%). 
3│RESULTS
3.1│Study population
Fifty-five of the 69 randomised patients collected 24-hour urines at both the pre-treatment and final on-
drug (Week-52) visit. In one patient (1.8%; randomised to exenatide), urine-collection was considered 
inadequate, and as such, a total of 54 patients are included in current analysis (evaluable population; 
Appendix-S2). Demographic and baseline clinical characteristics were well-balanced between groups 
(Table). In addition to metformin, all patients used other drugs at baseline, mostly antihypertensive 
drugs (RAS-inhibitors 53.7%, diuretics 20.3%, beta-blockers 35.2%, calcium-channel blockers 14.8%), 
statins (50.0%), and platelet-aggregation-inhibitors (44.4%). Numerically fewer patients randomised to 
exenatide (N=12; 46.2%) compared to iGlar (N=17; 60.7%) used RAS-inhibitor-therapy before 
enrolment. During the course of the study, iGlar dose was 19.2±1.4 units/day at Week-4, reaching a 
plateau of 34.9±3.6 units/day at Week-52.
3.2│Effects on renal efficacy-endpoints
At baseline, none of the patients had CrCl <60 mL/min/1.73m2, and 13.7% (N=7; 2 randomised to 
exenatide, 5 randomised to iGlar) were categorized to have microalbuminuria (UAE >30 mg/24-hour or 
UACR ≥3 mg/mmol). None of the patients had macroalbuminuria (UAE>300 mg/24-hour or UACR ≥30 
mg/mmol). CrCl did not change in either treatment-group from baseline to Week-52 (Figure-1A, 
Appendix-S3); mean±SEM change was -3.7±5.1 mL/min/1.73m2 with exenatide (P=0.473; baseline 
103.3±5.1 mL/min/1.73m2) and -1.3±5.6 mL/min/1.73m2 with iGlar (P=0.821; baseline 108.1±5.5 
mL/min/1.73m2); baseline-adjusted treatment-difference -5.2 (95% CI -18.9 to 8.6; P=0.451) 
mL/min/1.73m2. UAE and UACR remained unaffected with exenatide, and were significantly reduced 
from baseline to Week-52 with iGlar (P<0.05 for both); baseline-corrected risk-ratios did not reach 
statistical significance (Figures-1B/1C, Appendix-S3). One patient in the exenatide-arm progressed 
from normo- to microalbuminuria from baseline to Week-52, while two patients allocated to iGlar 
regressed from micro- to normoalbuminuria. Change in urine volume/24-hours tended to decrease 
with exenatide (-249±129 mL; P=0.065), and increase with iGlar (191±110 mL; P=0.094); baseline-
adjusted treatment-difference -427 mL (-750 to -103 mL; P=0.011). Treatment-differences in overall 
eGFR-trajectory (Figure-1D), and rate of change in eGFR for the three specified time-periods (Figure-
1E) were not observed. From baseline to Week-4 (period-1), there was a short-term decrease in eGFR 
in the iGlar-group (P=0.034) and exenatide-group (P=0.069); P>0.05 for between-group comparisons. 
During chronic administration (period-2; from Week-4 to Week-52), eGFR remained stable with 
exenatide, and tended to increase with iGlar (P=0.092). After cessation of study-drugs (period-3; 
Week-52 to follow-up visit Week-56), eGFR remained unchanged (P>0.05). There were no adverse 
events (AEs) reflecting potential acute renal failure with either treatment.
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3.3│Effects on renal risk-factors
Changes in renal risk-factors are shown in Figure-2 and Appendix-S3. HbA1c (baseline 
7.5±0.9%;58±10mmol/mol) decreased in both groups (P<0.001); at Week-52, HbA1c was reduced by 
0.80±0.10%;%;-9±1mmol/mol with exenatide and 0.79±0.14%%;-9±1mmol/mol with iGlar (baseline-
corrected treatment-difference 0.02% [95% CI -0.31 to 0.42; P=0.749). Both treatments decreased 
FPG from baseline to Week-52 (-1.48±0.30 mmol/L with exenatide, -3.05±0.42 mmol/L with iGlar); 
treatment-difference 1.90 mmol/L (95% CI 1.25 to 2.56; P<0.001). Bodyweight at baseline was 
91.9±13.9 kg; by Week-52, exenatide-treated patients achieved weight-loss of 4.1±0.8 kg, versus a 
non-significant gain of 1.3±1.0 with iGlar (treatment-difference -5.4 (95% CI -7.9 to -2.87; P<0.001). 
No within- or between-group differences were seen in BP and PUA after 52-weeks. Exenatide 
decreased LDL-cholesterol (-0.30±0.12; P=0.023) from baseline to Week-52, but no significant 
treatment-differences in lipids were observed. Absolute time-averaged mean and delta FPG-levels 
differed between-groups in favour of iGlar (P≤0.001), while time-averaged mean change from baseline 
in bodyweight favoured exenatide (P<0.001); no other between-group differences in time-averaged 
means or deltas were observed (Appendix-S4).
3.4│Exploratory correlation-analyses
Correlation-analyses between changes in renal-endpoints and time-averaged changes in renal risk-
factors are presented in Appendix-S5. In the entire cohort, changes in CrCl were negatively correlated 
with changes in PUA (r=-0.303, P=0.031), driven by those on iGlar (r=-0.499, P=0.009). Changes in 
UAE and UACR correlated positively with changes in HbA1c, FPG and systolic-BP (Appendix-S5). In 
the iGlar-group, changes in UAE and UACR correlated positively with systolic-BP (both P<0.05), while 
UACR was non-significantly correlated with HbA1c (r=0.369, P=0.076). In the exenatide-group, 
changes in UACR correlated with systolic-BP (r=0.496, P=0.022) and non-significantly with PUA (r=-
0.405, P=0.068), while changes in UAE tended to correlate with LDL-cholesterol (r=0.373, P=0.088).
4│DISCUSSION
In this post-hoc analysis, among metformin-treated T2DM patients without overt nephropathy, one-
year treatment with exenatide twice-daily does not affect 24-hour CrCl, albuminuria or eGFR-trajectory 
compared to titrated iGlar. Correlation-analyses suggested that individual albuminuria-lowering effects 
were driven by changes in systolic-BP for both treatments, while HbA1c-lowering may have 
contributed to the modest UACR-improvement with iGlar.
Secondary and exploratory analyses of three landmark CVOTs indicated that short- and long-
acting GLP-1RAs (lixisenatide(4,5), liraglutide(6) and semaglutide(7)) slow progression of albuminuria 
compared to placebo in patients with T2DM and moderate-to-high cardiovascular risk. Importantly, 
subsequent mediation-analyses suggested that renal benefits were (at least in-part) glucose-
independent.(4,5,10) A placebo-controlled, cross-over trial in 32 patients with T2DM and persistent 
albuminuria also concluded that the observed 32% UACR-reduction with liraglutide was partly 
glucose-independent.(11) In LEADER, liraglutide slowed eGFR-decline by 2% compared to placebo 
after 36-months of follow-up (-7.44 vs -7.82 mL/min/1.73m2, respectively).(6) Although cardiovascular-
safety of the extended-release (once-weekly) formulation of exenatide was demonstrated in 
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EXSCEL(12), renal outcome data of this CVOT are still eagerly awaited. Not all placebo-controlled 
trials showed favourable effects of GLP-1RAs on albuminuria and estimated/measured GFR(3,13-15), 
and some controversy regarding the renoprotective efficacy of this drug-class remains. As 
microvascular complications are related to HbA1c-levels, and post-hoc mediation-analyses can only 
speculate about mechanisms driving the result, suggestions of renoprotection “beyond glycaemic 
control” require confirmation in dedicated trials that safeguard glycaemic-equipoise.
As a result of the use of an active comparator-arm (iGlar) in current study, long-term differences in 
HbA1c between treatments were minimal (0.02%), and direct comparison between two relevant 
glucose-lowering drug-choices to intensify metformin is possible. The neutral effect of exenatide on 
renal-endpoints in our head-to-head RCT are in line with a 2014 observational study, that examined 
historical data from electronic medical-records in routine US-practice.(16) That study also showed no 
differences between exenatide twice-daily and iGlar in change in renal function or albuminuria at 1-
year in T2DM patients typically without nephropathy. In contrast, exenatide twice-daily vs glimepiride 
resulted in greater 24-hour UAE-reductions in microalbuminuric T2DM patients after 26-weeks.(17) 
Integrated data from dulaglutide registration trials indicated lower UACRs upon treatment with this 
long-acting GLP-1RA than with iGlar and other active comparators in 6005 T2DM patients, with and 
without CKD.(18) Fewer patients on dulaglutide compared to iGlar experience a 40%-decline in eGFR 
at any point during the one-year treatment-period.(18) Finally, in the 52-week AWARD-7 trial, eGFR 
was higher with dulaglutide compared to iGlar at end-of-trial, without between-group differences in 
albuminuria, in 577 patients with T2DM and moderate-to-severe CKD.(19) The discrepant effects of 
GLP-1RA-therapy on renal endpoints are incompletely understood, but may relate to 
pharmacokinetic/-dynamic differences between compounds (short-acting vs long-acting GLP-1RAs) 
and/or studied T2DM populations (non-CKD vs CKD-patients).(3)
Numerous mechanisms by which GLP-1RAs may improve renal outcomes are postulated(1,3). 
First, as GLP-1R-expression has been reported in various locations in the kidney(3), direct actions of 
GLP-1RAs on renal physiology were expected. Indeed, GLP-1RA-administration induces natriuresis 
and diuresis in healthy males(20) and T2DM patients(21-23), attributed to blockade of sodium-
hydrogen exchange in the proximal tubule.(3) Through the consequent increased sodium-delivery to 
the distally located macula densa, GLP-1RAs could –in keeping with sodium-glucose co-transporter 
(SGLT)2-inhibitors– activate tubuloglomerular feedback (TGF), leading to pre-glomerular 
vasoconstriction and a resulting decrease in glomerular hyperfiltration.(24) Such renal vasomodulatory 
effect would cause an acute decrease in GFR, followed by a smaller decline in renal function during 
continued treatment, as described with RAS-inhibitors and SGLT2-inhibitors.(1,24,25) Interestingly, in 
the current trial, both exenatide and iGlar-treated patients displayed such a pattern of change in renal 
function (i.e. a small [~3.5%] short-term decrease, followed by eGFR-stabilization), suggestive of an 
acute reduction in intraglomerular-pressure.(24) Although similar suggestive falls in eGFR were seen 
promptly after liraglutide-treatment (13,14,26), these changes did not differ from placebo, and were 
quantitatively smaller than those seen upon RAS- and SGLT2-inhibition.(24) Consistent, mechanistic-
studies in humans that used gold-standard methodology to assess renal haemodynamics in the 
fasting(14,21,22) and postprandial(23) state, also indicate that GLP-1RAs harbour a neutral, or more 
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variable, effect on measured-GFR, effective renal plasma-flow and estimated intraglomerular-pressure 
in T2DM patients. Moreover, in contrast to reports on RAS- and SGLT2-inhibitors(24), we did not 
observe a reversible change in eGFR after discontinuation of either study-drug that would suggest 
involvement of a haemodynamic-mechanism. Acute changes in eGFR seen with exenatide and iGlar 
in current study may likely be the result of glucose-lowering per-se. Notably, renal haemodynamic 
actions of GLP-1RAs do not only involve TGF-activation, but are likely more complex  (e.g. involving 
GLP-1R-mediated vasodilation of pre-glomerular arterioles [opposing a TGF-mediated 
vasoconstrictive-response] and indirect vasomodulatory actions on postglomerular-arterioles) and may 
vary between individuals. Second, modest benefits of GLP-1RAs on the renal risk-profile in T2DM are 
also hypothesised to indirectly contribute to their renoprotective efficacy.(1) However, in current study, 
and despite reductions in bodyweight and LDL-cholesterol in the exenatide-group, the pleiotropic 
effects of GLP-1RA-therapy did not translate into a glucose-independent benefit on renal endpoints. 
Although drug-effects on bodyweight and cholesterol have been shown to be relevant in reducing 
patients’ renal risk(1), other off-target effects (including unfavourable actions) of GLP-1RAs in 
individual patients should also be taken into account, and may offset any theorised renoprotection. 
Notably, all renal risk variables in current analysis were assessed in the fasting state, and may as such 
not fully reflect the net risk of the individual patient over 24-hours (i.e. involving ingestion of multiple 
meals). To illustrate, short-acting GLP-1RAs (exenatide twice-daily and lixisenatide) may on the one 
hand have a sustained favourable effect on meal-induced dysglycaemia, dyslipidaemia and 
inflammatory/oxidative-stress markers in T2DM patients (27), but may on the other hand –and in 
contrast to long-acting GLP-1RAs– increase postprandial-BP compared to insulin.(23,28) It is tempting 
to speculate that 24-hour integrated pleiotropic effects (i.e. the ratio of favourable/unfavourable effects 
in both the fasting and postprandial state) differ between short- and long-acting GLP-1RAs, and may in 
part help explain dissimilarities between compounds in glucose-independent effect on renal and other 
outcomes. Comparative studies that generate an integrated risk score (such as the PRE-score(29)) 
upon treatment with GLP-1RAs with different pharmacokinetic profiles are needed to explore this 
principle in detail. Finally, we observed a notable correlation between albuminuria-lowering and time-
averaged decrements in fasting-BP with exenatide, which is in line with one of the suggested anti-
albuminuric drivers of liraglutide-treatment(11), and reveals an individual responder-characteristic in 
terms of renoprotection with this GLP-1RA.
As GLP-1RAs are associated with nausea, vomiting, diarrhoea and acute natriuresis and increased 
diuresis(2,3), concerns arose around volume-related renal safety issues (i.e. acute kidney injury) in 
prone T2DM patients.(30) Our results, as well as data from retrospective and large-sized prospective 
registration studies(3,15), do not confirm 11 early-reported cases of exenatide-induced acute 
interstitial nephritis and tubular necrosis.(30) Interestingly, we did find an intriguing reduction in 24-
hour urine-output of ~425 mL after 52-weeks of exenatide versus iGlar. This is in line with our previous 
observation that exenatide-infusion reduces urinary-flow, free water-clearance and fractional urea-
excretion in T2DM patients.(21) 
Our study has some limitations that merit consideration. First, this was a post-hoc analysis of an 
RCT that was not originally designed to assess treatment-effects on renal-variables. Our results can 
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therefore only be interpreted as hypothesis-generating. Second, the external validity (generalizability) 
is limited by the nature of the participants studied (i.e. those with preserved/normal renal function and 
typically no albuminuria); potential renal benefits of GLP-1RAs may be seen particularly in those 
patients with more advanced-CKD.(6) Third, CrCl and UAE using 24-hour urine-collections are 
susceptible to variation and collection errors. To enhance quality of our 24-hour urine-collection 
results, participants were rigorously instructed on the procedure, and data of likely undercollectors 
(based on expected daily creatinine-excretion given DEXA-scan-measured LBM) were excluded.
In conclusion, among T2DM patients without overt nephropathy, one-year treatment with exenatide 
twice-daily did not affect renal function-decline or onset and progression of albuminuria compared to 
iGlar, despite modest benefits on patients’ renal risk-profile. Long-term renal outcome studies that 
compare GLP-1RAs with different pharmacokinetic-profiles, and use relevant active comparators, in 
T2DM patients with more advanced CKD are needed to further assess the suggested glucose-
independent renoprotective efficacy of this drug-class.
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Female sex, N (%) 10 (38.5) 7 (25.0) 0.287
Age, years 59.7 ±8.1 59.4 ±7.5 0.853
Bodyweight, kg 90.1 ±14.1 93.5 ±13.8 0.375
Body Mass Index, kg/m2 30.4 ±4.1 30.4 ±3.7 0.988
Daily metformin dose, mg 1795 ±708 1591 ±786 0.366
Diuretic use, N (%) 5 (19.2) 6 (21.4) 0.841
RAS-inhibitor use, N (%) 12 (46.2) 17 (60.7) 0.284
ACE-inhibitor, N (%) 10 (38.5) 9 (32.1) 0.627
ARB, N (%) 2 (7.7) 8 (28.6) 0.048
Beta-blocker use, N (%) 8 (30.8) 11 (39.3) 0.513
Calcium channel blocker use, N (%) 4 (15.4) 4 (14.3) 0.910
Statin use, N (%) 9 (34.6) 18 (64.3) 0.029
Platelet-aggregation inhibitor use, N (%) 11 (42.3) 13 (46.4) 0.761
HbA1c, % 7.53 ±0.98 7.45 ±0.77 0.748
HbA1c, mmol/mol 58 ±10 58 ±8 0.748
Fasting plasma glucose, mmol/L 9.39 ±1.83 9.02 ±2.03 0.486
Total cholesterol, mmol/L 4.94 [4.19-5.55] 4.75 [4.14-5.61] 0.749
HDL-cholesterol, mmol/L 1.13 [1.01-1.41] 1.17 [1.04-1.38] 0.952
LDL-cholesterol, mmol/L 3.04 [2.61-3.52] 2.80 [2.29-3.53] 0.279
Triglycerides, mmol/L 1.63 [1.29-2.44] 2.29 [1.54-3.07] 0.119
Systolic-BP, mmHg 136 ±13 136 ±14 0.955
Diastolic-BP, mmHg 81 ±8 80 ±6 0.877
Heart rate, mmHg 69 ±12 71 ±10 0.624
eGFR, mL/min/1.73m2 84.7 ±17.0 87.8 ±14.9 0.473
Albumin excretion rate, mg/24h 7.36 [5.91-15.14] 10.90 [7.12-19.56] 0.263
Albumin-creatinine ratio, mg/mmol 0.63 [0.41-1.27] 0.77 [0.54-1.79] 0.477
Microalbuminuria, N (%) 2 (7.7) 5 (17.9) 0.318
Data are presented as mean±SD, median [inter-quartile range] or N (%). Albuminuria status at baseline was 
unavailable in 3 patients randomised to exenatide twice-daily and 1 patient randomised to insulin glargine. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; BID, twice-daily; BP, 
blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; RAS, renin-angiotensin-system.
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FIGURE 1│ Change from Baseline to Week-52 in urinary albumin excretion (A; median IQR), 
creatinine clearance (B; mean ±SEM) and urinary albumin-creatinine ratio (C; median IQR). 
Mean ±SEM changes in estimated glomerular filtration rate (eGFR) over time (D), and during 
pre-specified time-periods (E).
 
FIGURE 2│Change in renal risk factors over time
  
  
 
